Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY3–36 but resistant to ghrelin

Abstract

OBJECTIVE: The role of the melanocortin system in the feeding effects of peripheral peptide YY3–36 (PYY3–36) and ghrelin was investigated using the agouti (Ay/a) mouse as a model of abnormal melanocortin signalling. Furthermore, we examined whether the ectopic expression of agouti protein in Ay/a mice results in complete MC4-R inhibition, by studying the effects of peripheral alpha-melanocyte-stimulating hormone (α-MSH) and leptin on food intake.

DESIGN: Adult Ay/a mice were studied in the pre-obese state (7–8 weeks) and obese state (14–15 weeks). Animals received PYY3–36 (0.02 μmol/kg), NDP-α-MSH (0.2 μmol/kg), leptin (2 μmol/kg) (all 24 h fasted state) and ghrelin (0.2 μmol/kg) (fed state) by intraperitoneal (i.p.) injection. Age-matched Ay/a controls received i.p. saline. A separate cohort of wild-type (WT), age-matched controls received the same peptide dose or saline. Food intake was measured at 1, 2, 4, 8 and 24 h post-injection and compared in all four groups. Plasma leptin-, ghrelin- and PYY-like immunoreactivity (IR) were measured using radioimmunoassay (RIA).

RESULTS: At 2 h post-injection, PYY3–36 reduced food intake in pre-obese and obese Ay/a mice, whereas ghrelin had no effect. Plasma ghrelin levels were significantly reduced in pre-obese and obese Ay/a mice compared to WT controls. Peripheral administration of NDP-α-MSH and leptin acutely suppressed feeding (0–2 h) in pre-obese and obese Ay/a mice.

CONCLUSIONS: Responsiveness of pre-obese and obese Ay/a mice to PYY3–36 suggests that the melanocortin system may not be essential for the anorectic effects of this peptide. Melanocortinergic antagonism by agouti protein in Ay/a mice may be sufficient to block the effects of endogenous, but not exogenous PYY3–36, α-MSH and leptin. The mechanism underlying ghrelin resistance in Ay/a mice may result from antagonism of hypothalamic melanocortin receptors-4 by agouti protein, supporting a role for the melanocortin system in mediating ghrelin's actions.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

References

  1. Wolff GL, Roberts DW, Mountjoy KG . Physiological consequences of ectopic agouti gene expression: the yellow obese mouse syndrome. Physiol Genomics 1999; 1: 151–163.

    CAS  Article  Google Scholar 

  2. Klebig ML, Wilkinson JE, Geisler JG, Woychik RP . Ectopic expression of the agouti gene in transgenic mice causes obesity features of type ii diabetes and yellow fur. Proc Natl Acad Sci USA 1995; 92: 4728–4732.

    CAS  Article  Google Scholar 

  3. Perry WL, Hustad CM, Swing DA, Jenkins NA, Copeland NG . A transgenic mouse assay for agouti protein activity. Genetics 1995; 140: 267–274.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RP, Wilkison WO, Cone RD . Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994; 371: 799–802.

    CAS  Article  Google Scholar 

  5. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F . Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88: 131–141.

    CAS  Article  Google Scholar 

  6. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS . Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997; 278: 135–138.

    CAS  Article  Google Scholar 

  7. Graham M, Shutter JR, Sarmiento U, Sarosi I, Stark KL . Overexpression of agrt leads to obesity in transgenic mice. Nat Genet 1997; 17: 273–274.

    CAS  Article  Google Scholar 

  8. Broberger C, Johansen J, Johansson C, Schalling M, Hokfelt T . The neuropeptide Y/Agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci USA 1998; 95: 15043–15048.

    CAS  Article  Google Scholar 

  9. Hahn TM, Breininger JF, Baskin DG, Schwartz MW . Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1998; 1: 271–272.

    CAS  Article  Google Scholar 

  10. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM . Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425–432.

    CAS  Article  Google Scholar 

  11. Cheung CC, Clifton DK, Steiner RA . Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 1997; 138: 4489–4492.

    CAS  Article  Google Scholar 

  12. Mercer JG, Hoggard N, Williams LM, Lawrence CB, Hannah LT, Morgan PJ, Trayhurn P . Coexpression of leptin receptor and preproneuropeptide Y MRNA in arcuate nucleus of mouse hypothalamus. J Neuroendocrinol 1996; 8: 733–735.

    CAS  Article  Google Scholar 

  13. Tsuruta Y, Yoshimatsu H, Hidaka S, Kondou S, Okamoto K, Sakata T . Hyperleptinemia in A(y)/a mice upregulates arcuate cocaine- and amphetamine-regulated transcript expression. Am J Physiol Endocrinol Metab 2002; 282: E967–E973.

    CAS  Article  Google Scholar 

  14. Kesterson RA, Huszar D, Lynch CA, Simerly RB, Cone RD . Induction of neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. Mol Endocrinol 1997; 11: 630–637.

    CAS  Article  Google Scholar 

  15. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM . Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 1997; 94: 8878–8883.

    CAS  Article  Google Scholar 

  16. Wilson BD, Bagnol D, Kaelin CB, Ollmann MM, Gantz I, Watson SJ, Barsh GS . Physiological and anatomical circuitry between agouti-related protein and leptin signaling. Endocrinology 1999; 140: 2387–2397.

    CAS  Article  Google Scholar 

  17. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K . Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656–660.

    CAS  Article  Google Scholar 

  18. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, Bloom SR . The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141: 4325–4328.

    CAS  Article  Google Scholar 

  19. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri S, Stanley SA, Ghatei MA, Bloom SR . Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001; 50: 2540–2547.

    CAS  Article  Google Scholar 

  20. Tschop M, Smiley DL, Heiman ML . Ghrelin induces adiposity in rodents. Nature 2000; 407: 908–913.

    CAS  Article  Google Scholar 

  21. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S . A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194–198.

    CAS  Article  Google Scholar 

  22. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K . Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001; 50: 227–232.

    CAS  Article  Google Scholar 

  23. Wren AM, Small CJ, Fribbens CV, Neary NM, Ward HL, Seal LJ, Ghatei MA, Bloom SR . The hypothalamic mechanisms of the hypophysiotropic action of ghrelin. Neuroendocrinology 2002; 76: 316–324.

    CAS  Article  Google Scholar 

  24. Tatemoto K . Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci USA 1982; 79: 2514–2518.

    CAS  Article  Google Scholar 

  25. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR . Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 2002; 418: 650–654.

    CAS  Article  Google Scholar 

  26. Zemel MB, Moore JW, Moustaid N, Kim JH, Nichols JS, Blanchard SG, Parks DJ, Harris C, Lee FW, Grizzle M, James M, Wilkison WO . Effects of a potent melanocortin agonist on the diabetic/obese phenotype in yellow mice. Int J Obes Relat Metab Disord 1998; 22: 678–683.

    CAS  Article  Google Scholar 

  27. Boston BA, Blaydon KM, Varnerin J, Cone RD . Independent and additive effects of central POMC and leptin pathways on murine obesity. Science 1997; 278: 1641–1644.

    CAS  Article  Google Scholar 

  28. Bolton AE, Hunter WM . The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem J 1973; 133: 529–539.

    CAS  Article  Google Scholar 

  29. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR . Inhibition of food intake in obese subjects by peptide YY3–36 . N Engl J Med 2003; 349: 941–948.

    CAS  Article  Google Scholar 

  30. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S . Leptin levels in human and rodent: measurement of plasma leptin and Ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155–1161.

    CAS  Article  Google Scholar 

  31. Correia ML, Haynes WG, Rahmouni K, Morgan DA, Sivitz WI, Mark AL . The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 2002; 51: 439–442.

    CAS  Article  Google Scholar 

  32. De Souza J, Butler AA, Cone RD . Disproportionate inhibition of feeding in A(y) mice by certain stressors: a cautionary note. Neuroendocrinology 2000; 72: 126–132.

    CAS  Article  Google Scholar 

  33. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS . Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68–100.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD . Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997; 385: 165–168.

    CAS  Article  Google Scholar 

  35. Harris RB, Mitchell TD, Mynatt RL . Leptin responsiveness in mice that ectopically express agouti protein. Physiol Behav 2002; 75: 159–167.

    CAS  Article  Google Scholar 

  36. Hewson AK, Dickson SL . Systemic administration of ghrelin in-duces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J Neuroendocrinol 2000; 12: 1047–1049.

    CAS  Article  Google Scholar 

  37. Wang L, Saint-Pierre DH, Tache Y . Peripheral ghrelin selectively increases Fos expression in neuropeptide Y-synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci Lett 2002; 325: 47–51.

    CAS  Article  Google Scholar 

  38. Ariyasu H, Takaya K, Hosoda H, Iwakura H, Ebihara K, Mori K, Ogawa Y, Hosoda K, Akamizu T, Kojima M, Kangawa K, Nakao K . Delayed short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the active form of ghrelin. Endocrinology 2002; 143: 3341–3350.

    CAS  Article  Google Scholar 

  39. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML . Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707–709.

    CAS  Article  Google Scholar 

  40. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A, Weigle DS . Elevated plasma ghrelin levels in prader willi syndrome. Nat Med 2002; 8: 643–644.

    CAS  Article  Google Scholar 

  41. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S . Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87: 240–244.

    CAS  Article  Google Scholar 

  42. Haqq AM, Farooqi IS, O'Rahilly S, Stadler DD, Rosenfeld RG, Pratt KL, LaFranchi SH, Purnell JQ . Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in prader-willi syndrome. J Clin Endocrinol Metab 2003; 88: 174–178.

    CAS  Article  Google Scholar 

  43. Barazzoni R, Zanetti M, Stebel M, Biolo G, Cattin L, Guarnieri G . Hyperleptinemia prevents increased plasma ghrelin concentration during short-term moderate caloric restriction in rats. Gastroenterology 2003; 124: 1188–1192.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank K Murphy, K Smith and A Wren for their helpful comments while reading this manuscript. NMM is a Wellcome Trust Clinical Training Fellow. This work is supported by an MRC programme Grant G7811974 (Bloom, Ghatei and Small).

Author information

Affiliations

Authors

Corresponding author

Correspondence to S R Bloom.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Martin, N., Small, C., Sajedi, A. et al. Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY3–36 but resistant to ghrelin. Int J Obes 28, 886–893 (2004). https://doi.org/10.1038/sj.ijo.0802646

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0802646

Keywords

  • agouti
  • PYY3–36
  • ghrelin
  • leptin
  • α-MSH

Further reading

Search

Quick links